An open-label, pilot study to compare the safety and immunogenicity of an alternate dosing schedule (2-5 weeks, 2, and 4 months) for pentavalent rotavirus vaccine (RotaTeq) to the standard recommended schedule (2, 4 and 6 months).

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2013 - June 30, 2021